Viridian's Decline Misses Crucial Imbalance: Advantage in Safety and Brand Loyalty Compared to Amgen’s Latest Subcutaneous Standard

Market Turmoil Following Amgen’s Announcement

Amgen’s recent news sent shockwaves through the market, triggering a sharp decline in Viridian Therapeutics shares. The stock tumbled by 26% to close at $13.97 on Monday, continuing a downward trend that began earlier in the month—even after Viridian had shared encouraging Phase 3 results for its subcutaneous therapy, Elegrobart. The catalyst for this selloff was Amgen’s report of strong topline Phase 3 data for its subcutaneous Tepezza (OBI), which achieved a 77% proptosis response rate. After hours on April 10, Viridian’s stock slipped further to $14.58, raising the question: is this a rational adjustment to new competition, or an overreaction to shifting expectations?

The central issue is whether investors have already factored in the worst-case scenario for Viridian. The company’s REVEAL-1 trial, announced in March, showed a responder rate between 54% and 63%. Amgen’s higher 77% result immediately cast doubts on Viridian’s competitive standing. The market’s 18.4% drop in response suggests deep concern that Amgen’s advantage may be too great to overcome. After a period of optimism around Viridian’s data, Amgen’s results have seemingly reset the bar for success, especially since its subcutaneous Tepezza claims to match the efficacy of IV therapy with added convenience.

However, this reaction may be premature. The market is focusing on a single efficacy metric, while the broader competitive landscape is more nuanced. Safety, ease of use, and cost will all influence which therapy gains traction. For now, though, sentiment has shifted dramatically, with Viridian now being measured against a new, higher standard. Investors must decide if this selloff is a justified reassessment of Viridian’s prospects or an overreaction to a headline number that doesn’t capture the full picture.

Competitive Dynamics: Beyond the Headline Numbers

The market’s fixation on Amgen’s 77% response rate oversimplifies a complex situation. The real competitive story involves entrenched positions and risk asymmetry. Amgen’s TEPEZZA IV has treated over 25,000 patients globally since its 2020 approval, creating strong brand loyalty and physician familiarity. Convincing doctors to switch from a well-established IV therapy to a new subcutaneous option will require more than just a marginally better efficacy rate.

Viridian’s potential strength lies in the practical aspects of its therapy. Elegrobart is administered subcutaneously every four or eight weeks, which could be more convenient for patients and less costly for the healthcare system compared to the eight IV infusions required by the current standard. Additionally, Viridian’s data indicate lower rates of hearing impairment, a known side effect of anti-IGF-1R drugs, which could be a significant advantage if Amgen’s formulation does not improve on this front.

Currently, the market appears to be assuming the worst for Viridian while underestimating the hurdles Amgen faces. Amgen’s OBI is simply a new delivery method for an existing drug, not a new compound. Its commercial success will depend on persuading physicians and payers that the convenience of subcutaneous administration justifies any additional costs or safety concerns. In contrast, Viridian is introducing a new subcutaneous therapy from the outset, which could be a more straightforward commercial proposition if its efficacy and safety hold up in broader use.

In summary, while the competitive landscape has shifted, it is not necessarily a clear win for Amgen. The market may be overestimating the threat posed by Amgen’s results while overlooking Viridian’s practical advantages and the inertia of established therapies. The ultimate outcome will depend on which company can best bridge the gap between clinical trial results and real-world adoption.

Financial Outlook: Risk and Opportunity

Viridian’s valuation has taken a hit, but its financial position remains strong. The company ended 2025 with $875 million in cash, providing ample resources to fund operations for several years and support its planned BLA submission in the first quarter of 2027. The recent stock decline, which has cut the share price by about half from early 2026 highs, likely reflects a scenario where Viridian’s commercial prospects are severely diminished. However, the company’s robust balance sheet means it can continue its development efforts without immediate financial strain.

This situation creates a classic risk/reward imbalance. The downside is clear: if Amgen’s subcutaneous Tepezza quickly dominates the market, Viridian’s ability to compete and set prices could be compromised. The company’s own Phase 3 data, showing a 54% to 63% response rate, falls short of Amgen’s 77%, fueling market fears. On the other hand, the upside depends on whether these concerns are exaggerated. Viridian’s therapy is a novel subcutaneous option from the start, potentially offering a cleaner commercial story than a new delivery method for an existing drug. Its favorable safety profile, especially regarding hearing impairment, could further differentiate it.

Upcoming milestones may help balance these risks. Viridian expects topline results from the REVEAL-2 trial in the second quarter of 2026, which will provide additional efficacy data in a different patient group. In the near term, the veligrotug PDUFA date on June 30, 2026 could be a significant value driver. If approved, veligrotug could generate revenue that extends Viridian’s cash runway and provides a financial anchor, regardless of how the competition with Amgen unfolds.

Ultimately, the market’s sharp reaction may have created a mispricing opportunity. While the steep drop in Viridian’s share price reflects skepticism about its long-term prospects, the company’s strong financial position and upcoming catalysts suggest the risk/reward profile has shifted. The next several quarters will reveal whether concerns about efficacy are justified or if Viridian can leverage its advantages to secure a meaningful market position.

Key Events and Risks Ahead

The investment case for Viridian now depends on several upcoming developments that could challenge the market’s current pessimism. The most important is the REVEAL-2 topline readout in Q2 2026, which will assess elegrobart in patients with chronic thyroid eye disease—a different group than those in the initial trial. These results will be crucial for establishing the drug’s effectiveness across a broader spectrum and for building a more comprehensive clinical profile to counter Amgen’s benchmark.

Investors should also watch for any regulatory or commercial moves from Amgen or other competitors. The key question is whether the convenience of subcutaneous Tepezza will translate into rapid market adoption. If Amgen is able to quickly launch and capture a large share of the active TED market, it could delay Viridian’s commercialization and impact its pricing power. Viridian’s timeline for a BLA submission in early 2027 could be complicated by a more crowded marketplace.

As with any pre-revenue biotech, execution risk remains high. Viridian must successfully navigate regulatory hurdles, manage its cash wisely, and prepare for commercialization—all while its stock trades at a significant discount from earlier highs. The near-term catalyst of the veligrotug PDUFA date offers a potential inflection point, with approval opening the door to commercial revenue that could further strengthen its financial position.

In conclusion, the risk/reward equation for Viridian has shifted. The market appears to have priced in a scenario where the company’s commercial prospects are severely threatened. The coming months will test whether these fears are warranted or if Viridian can capitalize on its practical advantages and forthcoming data to establish a solid foothold. The outcome of these key events will determine whether the current valuation is justified or simply a temporary response to a rapidly evolving competitive landscape.